Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule

Journal of Immunology

Volumn 170, Issue 6, 2003, Pages 3214-3222

  Pausa, Mario ^a   Pellis, Valentina ^a   Cinco, Marina ^a   Giulianini, Piero G ^a   Presani, Gianni ^b   Perticarari, Sandra ^b   Murgia, Rossella ^a   Tedesco, Francesco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Ist Ricovero Cura Carat Sci B G   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ANTIGEN RECOGNITION; ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BORRELIA BURGDORFERI; CELL KILLING; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; FLOW CYTOMETRY; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYME DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; STRAIN DIFFERENCE;

EID: 0037443666     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.6.3214     Document Type: Article

References (50)

1. Volanakis, J. E. 1998. Overview of the complement system. In The Human Complement System in Human and Disease. J. E. Volanakis and M. M. Frank, eds. Dekker, New York, p. 9.
2. Spear, G. T., N. S. Lurain, C. J. Parker, M. Ghassemi, G. H. Payne, and M. Saifuddin. 1995. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses: human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 155:4376.
3. Saifuddin, M., T. Hedayati, J. P. Atkinson, M. H. Holguin, C. J. Parker, and G. T. Spear. 1997. Human immunodeficiency virus type I incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78:1907.
4. Rautemaa, R., G. A. Jarvis, P. Marnila, and S. Meri. 1998. Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect. Immun. 66:1928.
5. Wurzner, R. 1999. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol. Immunol. 36:249.
6. Joiner, K. A. 1988. Complement evasion by bacteria and parasites. Annu. Rev. Microbiol. 42:201.
7. Yssel, H., M. C. Shanafelt, C. Soderberg, P. V. Schneider, J. Anzola, and G. Peltz. 1991. Borrelia burgdorferi activates a T helper type I-like T cell subset in Lyme arthritis. J. Exp. Med. 174:593.
8. Anguita, J., S. Samanta, B. Revilla, K. Suk, S. Das, S. W. Barthold, and E. Fikrig. 2000. Borrelia burgdorferi gene expression in vivo and spirochete pathogenicity. Infect. Immun. 68:1222.
9. Barbour, A. G. 1991. Molecular biology of antigenic variation in Lyme borreliosis and relapsing fever: a comparative analysis. Scand. J. Infect. Dis. Suppl. 77:88.
10. Klempner, M. S., R. Noring, and R. A. Rogers. 1993. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J. Infect. Dis. 167:1074.
11. Ma, Y., A. Sturrock, and J. J. Weis. 1991. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect. Immun. 59:671.
12. Montgomery, R. R., M. H. Nathanson, and S. E. Malawista. 1993. The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages: destruction, survival, recovery. J. Immunol. 150:909.
13. Girschick, H. J., H. I. Huppertz, H. Russmann, V. Krenn, and H. Karch. 1996. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol. Int. 16:125.
14. Chary-Valckenaere, I., B. Jaulhac, J. Champigneulle, Y. Piemont, D. Mainard, and J. Pourel. 1998. Ultrastructural demonstration of intracellular localization of Borrelia burgdorferi in Lyme arthritis. Br. J. Rheumatol. 37:468.
15. Kochi, S. K., and R. C. Johnson. 1988. Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect. Immun. 56:314.
16. Breitner-Ruddock, S., R. Wurzner, J. Schulze, and V. Brade. 1997. Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med. Microbiol. Immunol. 185:253.
17. Brade, V., I. Kleber, and G. Acker. 1992. Differences of two Borrelia burgdorferi strains in complement activation and serum resistance. Immunobiology 185:453.
18. Patarakul, K., M. F. Cole, and C. A. Hughes. 1999. Complement resistance in Borrelia burgdorferi strain 297: outer membrane proteins prevent MAC formation at lysis susceptible sites. Microb. Pathog. 27:25.
19. van Dam, A. P., H. Kuiper, K. Vos, A. Widjojokusumo, B. M. de Jongh, L. Spanjaard, A. C. Ramselaar, M. D. Kramer, and J. Dankert. 1993. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17:708.
20. Alitalo, A., T. Meri, L. Ramo, T. S. Jokiranta, T. Heikkila, I. J. Seppala, J. Oksi, M. Viljanen, and S. Meri. 2001. Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect. Immun. 69:3685.
21. Kraiczy, P., C. Skerka, M. Kirschfink, V. Brade, and P. F. Zipfel. 2001. Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur. J. Immunol. 31:1674.
22. Kraiczy, P., C. Skerka, M. Kirschfink, P. F. Zipfel, and V. Brade. 2001. Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates. Int. Immunopharmacol. 1:393.
23. Hellwage, J., T. Meri, T. Heikkila, A. Alitalo, J. Panelius, P. Lahdenne, I. J. Seppala, and S. Meri. 2000. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J. Biol. Chem. 11:11.
24. Kochi, S. K., R. C. Johnson, and A. P. Dalmasso. 1991. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi: role of antibody in formation of an effective membrane attack complex. J. Immunol. 146:3964.
25. Sugita, Y., Y. Nakano, and M. Tomita. 1988. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J. Biochem. 104:633.
26. Davies, A., and P. J. Lachmann. 1993. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol. Res. 12:258.
27. Holguin, M. H., L. R. Fredrick, N. J. Bernshaw, L. A. Wilcox, and C. I. Parker. 1989. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84:7.
28. Okada, N., R. Harada, T. Fujita, and H. Okada. 1989. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1:205.
29. Mollnes, T. E., T. Lea, M. Harboe, and J. Tschopp. 1985. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 22:183.
30. Davies, A., D. L. Simmons, G. Hale, R. A. Harrison, H. Tighe, P. J. Lachmann, and H. Waldmann. 1989. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170:637.
31. Bodian, D. L., S. J. Davis, B. P. Morgan, and N. K. Rushmere. 1997. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein. CD59. J. Exp. Med. 185:507.
32. Hogasen, K., T. E. Mollnes, and M. Harboe. 1992. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J. Biol. Chem. 267:23076.
33. Meri, S., B. P. Morgan. A. Davies, R. H. Daniels, M. G. Olavesen, H. Waldmann, and P. J. Lachmann. 1990. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1.
34. Tedesco, F., L, Roncelli, B. H, Petersen, V. Agnello, and J. M. Sodetz. 1990. Two distinct abnormalities in patients with C8α-α deficiency: low level of C8β chain and presence of dysfunctional C8α-γ subunit. J. Clin. Invest. 86:884.
35. Cinco, M., R. Murgia, M. Ruscio, and B. Andriolo. 1996. IgM and IgG significant reactivity to Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii among Italian patients affected by Lyme arthritis or neuroborreliosis. FEMS Immunol. Med. Microbiol. 14:159.
36. Garcia, R., L. Gusmani, R. Murgia, C. Guarnaccia, M. Cinco, and G. Rottini. 1998. Elastase is the only human neutrophil granule protein that alone is responsible for in vitro killing of Borrelia burgdorferi. Infect. Immun. 66:1408.
37. Helenius, A., E. Fries, H. Garoff, and K. Simons. 1976. Solubilization of the Semliki Forest virus membrane with sodium deoxycholate. Biochim. Biophys. Acta 436:319.
38. Tedesco, F., M. Pausa, E. Nardon, M. Introna, A. Mantovani, and A. Dobrina. 1997. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185:1619.
39. Lachmann, P. J., and R. A. Thompson. 1970. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Exp. Med. 131:643.
40. Morgan, B. P., and C. L. Harris. 1999. Fluid-phase regulators of the terminal pathway. In Complement Regulatory Proteins. Academic. San Diego. p. 138.
41. Rollins, S. A., J. Zhao, H. Ninomiya, and P. J. Sims. 1991. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 146:2345.
42. Ninomiya, H., and P. J. Sims. 1992. The human complement regulatory protein CD59 binds to the α-chain of C8 and to the "b"domain of C9. J. Biol. Chem. 267:13675
43. van Dam, A. P., A. Oei, R. Jaspars, C. Fijen, B. Wilske, L. Spanjaard, and J. Dankert. 1997. Complement-mediated serum sensitivity among spirochetes that cause Lyme disease. Infect. Immun. 65:1228.
44. Kochi, S. K., R. C. Johnson, and A. P. Dalmasso. 1993. Facilitation of complement-dependent killing of the Lyme disease spirochete, Borrelia burgdorferi, by specific immunoglobulin G Fab antibody fragments. Infect. Immun. 61:2532.
45. Fernie-King, B. A., D. J. Seilly, C. Willers, R. Wurzner, A. Davies, and P. J. Lachmann. 2001. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 103:390.
46. Rautemaa, R., H. Rautelin, P. Puolakkainen, A. Kokkola, P. Karkkainen, and S. Meri. 2001. Survival of Helicobacter pylori from complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology 120:470.
47. Albrecht, J. C., J. Nicholas, K. R. Cameron, C. Newman, B. Fleckenstein, and R. W. Honess. 1992. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology 190:527.
48. Braga, L. L., H. Ninomiya, J. J. McCoy, S. Eacker, T. Wiedmer, C. Pham, S. Wood, P. J. Sims, and W. A. Petri, Jr. 1992, Inhibition of the complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica. J. Clin. Invest. 90:1131.
49. Parizade, M., R. Amon, P. J. Lachmann, and Z. Fishelson. 1994. Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59. J. Exp. Med. 179:1625.
50. Sadziene, A., D. D. Thomas, and A. G. Barbour. 1995. Borrelia burgdorferi mutant lacking Osp: biological and immunological characterization. Infect. Immun. 63:1573.